amazon facebook_32 gplus_32 linkedin_32 pinterest_32 tumblr_32 twitter_32 website_32 youtube_32 email_32 rss_32

MySocialGoodNews is dedicated to sharing news about
social entrepreneurship, impact investing, philanthropy
and corporate social responsibility.

Crowdfunding for Social Good

Devin D. Thorpe

Devin Thorpe

Leonhardt’s Launchpads Expands into Playa Vista, LA Tech Capital

Leading innovation and startup accelerator focused on regenerative medtech and regenerative economy innovations is expanding into Playa Vista, California following Cedars Sinai, Yahoo, Imax, Google, YouTube, Facebook, USC Institute of Creative Technologies + USC Center for Body Computing and Honest Co. into Los Angeles’ leading tech startup community.

Press Release – Los Angeles, Playa Vista – September 27th, 2017 – Leonhardt’s Launchpads is enhancing our footprint in Southern California with new regional offices at Runway Playa Vista @ 12760 Millennium Drive and at WeWork Playa Vista @ 12655 W. Jefferson Blvd. Incubating/accelerating startups in the area will be invited to locate at WeWork’s co-working space with mentoring support from the walking distance Runway Playa Vista live work loft space.

The new branch office presence in Playa Vista will put Leonhardt’s Launchpads in the heart of the fastest growing tech startup community in all of California – Silicon Beach @ Playa Vista. The company’s headquarters is in Santa Monica @ WeWork, 520 Broadway Suite 200.

“We are excited to join the Playa Vista tech startup community with our beautiful new spaces. This is great place to live and work. I have moved my family here. Being at the site of Loyola Marymount University, 5.3 miles from our headquarters in Santa Monica, only 8 miles to UCLA, 16 miles to USC, 17 miles to the Los Angeles Biomedical Institute in Torrance, 27 miles to Caltech and our contract micro infusion pump development and manufacturing facility in Pasadena, 39 miles to our contract implantable bioelectric stimulator development facility in Santa Clarita, 42 miles to our bench top bioelectric stimulator manufacturer in Anaheim, 45 miles to UC Irvine and only 4.5 miles to the Los Angeles International Airport is ideal for our research and development collaborations”. stated Howard J. Leonhardt, Founder, Executive Chairman and CEO

Runway Playa Vista comprises more than 220,000 square feet of retail, 420 residential units and the office space. The mixed-use property is spread across 11 acres in the core of the growing Silicon Beach community. The Silicon Beach corridor from Santa Monica north to Playa Vista south is home to over 83% of the tech startups in Los Angeles. Leonhardt’s Launchpads Playa Vista joins Cedars Sinai, Yahoo, Google, YouTube, Facebook, Imax, the USC Institute of Creative Technologies + Center for Body Computing and Honest Co. in locating here.

Leonhardt’s Launchpads opened up a life science incubator in Northern California near Santa Rosa in 2008, an accelerator in Santa Monica in 2013, Salt Lake City, Utah in late 2015 and now in Playa Vista, California in 2017. Leonhardt’s Launchpads by Cal-X Stars Business Accelerator, Inc. is majority owned by Leonhardt Ventures (Leonhardt Vineyards LLC DBA Leonhardt Ventures) which has been patenting and developing devices for human organ regeneration and recovery since the early 1980’s (previously H.J. Leonhardt & Co.). In the 1980’s the team patented and developed the PolyCath line of cardiovascular balloon catheters, in the 1990’s the Taheri-Leonhardt (TALENT) stent graft and StentValve the first percutaneous heart valve. Since the 2000’s the team has pioneered heart and other organ regeneration with the combination of a bioelectric stimulator, a re-fillable micro infusion pump and a multi-component stem cells + growth factors composition. In 1988 Leonhardt affiliated research team members completed the first stem cell repair of damaged heart tissue in large animals followed in 2001 with the landmark first human non-surgical stem cell repair of a damaged heart in The Netherlands. In 1995 the team completed the historic first percutaneous repair of an aortic aneurysm in Melbourne, Australia and in 1999 with a team in Germany published the first study in The New England Journal of Medicine of aortic Type B dissection repair by non-surgical percutaneous endovascular means. Leonhardt inventions have been used to treat more the 400,000 patients to date. 26 organ regeneration and recovery startups and 4 regenerative economy platforms are in the Leonhardt’s Launchpads 2017 portfolio class – https://leonhardtventures.com/our-companies/#toggle-id-1. All of these startups have originated out of the Leonhardt Ventures venture creation lab and have gone through the CalXelerator 108 Days from Create To Great startup launch program – www.calxelerator.com The Leonhardt’s Launchpads business model is to accelerate each innovation and corresponding startup through first-in-man results and then seek a strategic partner/buyer. 25 of our 26 regenerative medtech startups are all based on the same patented core technology platform of a bioelectric stimulator + a micro infusion pump + a multi-component mixed stem cell + growth factor based organ regeneration composition. The Leonhardt team has developed and has patented or has patent pending over 16 bioelectric organ regeneration signals that control stem cell homing, proliferation, differentiation, new blood vessel growth and tissue and muscle regeneration. Patented and patent proten expressions include SDF-1, IGF-1, HGF, EGF, PDGF, VEGF, eNOS, HIF 1 Alpha, Activin A+B, Follistatin, IL-6, Anti-VEGF, RANKL, OPG, IL-1 and TNF A and Tropoelastin – link to patent pending – https://patents.justia.com/patent/20170266371

Howard J. Leonhardt has 21 issued U.S. patents related to organ regeneration and recovery and about 100 new patents claims pending with the U.S.P.T.O. – https://patents.justia.com/inventor/howard-j-leonhardt

The Leonhardt team announced earlier this year option licenses for patents from Caltech and Neuro Code Tech Holdings adding to its own estate of IP for advanced circulatory support, bioelectric cancer tumor treatment and bioelectric high blood pressure treatment technologies.

Leonhardt’s Launchpads has research lab space at BioInnovations Gateway in Utah with a number of bioengineers employed. Over 140 contract researchers, bioengineers and advisors are employed by Leonhardt’s Launchpads – https://leonhardtventures.com/team/. and https://calxstars.com/scientific-advisory-board/ The Leonhardt team has access to contract research lab space in both Northern and Southern California. The company employs a contract manufacturer in Anaheim, California for bench top bioelectric stimulators and in Santa Clarita, California for implantable bioelectric stimulator development, currently about the size of a quarter, pre-programmed with their patented and patent pending bioelectric signals. Leonhardt’s Launchpads has an exclusive relationship with Fluid Synchrony LLC of Pasadena, CA for the development and supply of OEM programmable, re-fillable micro infusion pumps for organ regeneration. Fluid Synchrony LLC has secured more than $2 million in National Science Foundation Small Business Innovation Research grant funding to develop this product. All catheter and polymer based devices are manufactured for all Leonhardt’s Launchpads startups by Biomerics headquartered in Utah and their subsidiary Biomerics Advanced Catheter in Minnesota. This includes the Second Heart Assist, Inc. www.secondheartinc.com circulatory assist catheter that recently successfully completed Phase I large animal studies at Tufts Medical Center in Boston.

“The Playa Vista branch will be ideal for integrating into research collaborations in the Los Angeles academic and tech communities” stated Alex Richardson Vice President of Engineering and Product Development

“The Runway Playa Vista live work loft space will dually serve as a place to stay for visiting scientists and research collaborators including our Chief Medical Officer Dr. Leslie Miller and Dr. Jorge Genovese our Vice President of Bioelectric Regeneration Research.” Leonhardt further stated.

Top 6 startups in portfolio likely targeted on schedule for first-in-man results in 2018*…

  1. OrthdontiCell – bioelectric accelerated tooth movement and stabilization (RANKL and OPG protein expression studies have been successful completed at our lab in Utah and in Argentina and a new study is about to begin at Forsyth Institute in Boston).
  2. VascuStim – bioelectric treatment of diabetic foot/leg uclers and ischemia (components of this technology have already achieved successful first in man results).
  3. Second Heart Assist, Inc. – circulatory assist support (successful large animal studies have been completed at Tufts Medical Center).
  4. Stem Cell Bra – breast tissue generation (successul large animal studies have been completed in Argentina).
  5. HairCell – hair regeneration (component of therapy has already completed clinical studies in Canada).
  6. BioLeonhardt – heart regeneration (components of this technology have already achieved successful first in man results).

Top 6 startups in portfolio likely targeted on schedule to reach first-in-man results in 2019*..

  1. CancerCell – 7 component bioelectric cancer tumor treatment therapy.
  2. CerebraCell – brain regeneration
  3. MyoStim ED – bioelectric erectile dysfunction treatment.
  4. SkinCell Stimulator by MyoStim Skin.
  5. PancreaCell – pancreas regeneration.
  6. PressureStim – bioelectric high blood pressure treatment.

Top 6 startups in portfolio likely targeted on schedule to achieve first-in-man results 2020*…

  1. Valvublator – heart valve decalcification and regeneration
  2. LiverCell – liver regeneration.
  3. BioPace – biological pacemaker.
  4. AortaCell. – aorta regeneration/aneurysm recovery.
  5. DentaCell – bioelectric and stem cell composition treatment for a number of dental disorders.
  6. EyeCell – eye regeneration.

* Subject to change.

The most ambitious long term development project that the Leonhardt team is undertaking is whole body regeneration with its startup BioLeonhardt Whole Body which pulls together into one platform all that has been learned in regenerating individual organs since the 1980’s – https://leonhardtventures.com/bioleonhardt-whole-body/

Leonhardt’s Launchpads Regenerative Economy portfolio includes The California Stock ExchangeTM under early stage development with hopes and aspirations to be a social good impact stock exchange of the future with new rules favoring the small investor and smaller companies – http://mysocialgoodnews.com/the-california-stock-exchange-tm-announces-progress-and-long-term-plan/ and The Kindheart Lionheart TV Network www.kindheartlionhearttv.com a social good impact online TV network with over 2 billion views across all its curated independently produced programs.

About Leonhardt’s Launchpads:

Founded in 2008 as a life science innovation incubator and accelerator in Northern California and set up headquarters in Santa Monica in 2013. Expanded into Utah in 2015 and Playa Vista, California in 2017. The company also utilizes WeWork work space in Pasadena close to Caltech and WeWork Manhattan Beach. Leonhardt’s Launchpads is currently accelerating 26 regenerative medtech and 4 regenerative economy startups. See web site – https://leonhardtventures.com/leonhardts-launchpads-utah/

About Leonhardt Ventures:

Founded in 1982 as the venture arm of inventor Howard J. Leonhardt. Over 21 issued U.S. patents. Over 33 startups founded. Filed as an California LLC (Leonhardt Vineyards DBA Leonhardt Ventures) in 2005. In 1980’s patented and developed PolyCath cardiovascular balloon catheters, in the 1990’s the TALENT stent graft and StentValve percutaneous heart valve, since the 2000’s pioneered stem cell based organ regeneration technologies. Web site www.leonhardtventures.com

Contacts: Brian Hardy Director of Marketing @ brian@leonhardtventures.com, Asli Gozoren Director of Investor Relations @ asli@leonhardtventures.com, Howard J. Leonhardt Executive Chairman & CEO howard@leonhardtventurses.com

Link to Leonhardt Ventures and Leonhardt’s Launchpads 2017 Annual Report > http://2ho06i23weps2hx3g346udzo-wpengine.netdna-ssl.com/wp-content/uploads/2017/08/cal-x_stars_annual-report_2017_v12_web.pdf

Forward-Looking Statements, Disclaimers & Risks Warnings:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company’s business strategy, the Company’s ability to develop and grow its business, the successful development of bioelectric, circulatory support, micro infusion pump or cellular therapies with respect to the Company’s research and development and pre-clinical + clinical evaluation efforts in connection with the Company’s bioelectric organ regeneration and recovery programs. The future of the regenerative medicine industry as a whole and the role of stem cells and cellular therapy, bioelectric stimulation and micro infusion pumps in that industry and the performance and planned expansion of the Company’s contract development and manufacturing business are unpredictable and uncertain and is wrought with high risks. The Company may not have adequate patent protection and may be found to be infringing on other patents. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report, Private Placement Memorandums and newsletter updates and in the Company’s other periodic filings with the SEC and state agencies. The Company’s further development is highly dependent on future medical and research developments and market acceptance, which is outside its control. The innovation accelerator business model based on simultaneously developing 30+ products and startups at once with a small staff and a small budget leaves the company at greater risks than other stand alone startups. Information on all associated web sites and other associated materials may not always be up to date and accurate despite best effort attempts. If you have any specific questions or require clarification on any points of concern please write directly to our Executive Chairman & CEO at howard@leonhardtventures.com or Asli Gozoren our Director of Investor Relations at asli@leonhardtventures.com Leonhardt’s Launchpads innovations are very early stage developments not yet proven for safety or efficacy in controlled statistically significant clinical trials and its products are not available for sale and are limited when available for Investigational Use Only.


Never miss another article! Join Devin here: http://bit.ly/joindevin.

Don't miss any Good News!
Subscribe to news from MySocialGoodNews.com!
* = required field
Content I want:



Find Us On

amazon facebook_32 gplus_32 linkedin_32 pinterest_32 tumblr_32 twitter_32 website_32 youtube_32 email_32 rss_32